Compare ONC & SLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | SLF |
|---|---|---|
| Founded | 2010 | 1871 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8B | 33.0B |
| IPO Year | N/A | N/A |
| Metric | ONC | SLF |
|---|---|---|
| Price | $322.79 | $58.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $369.50 | $84.00 |
| AVG Volume (30 Days) | 332.1K | ★ 534.9K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.58 | ★ 3.77 |
| Revenue | $4,972,687,000.00 | ★ $24,759,313,366.00 |
| Revenue This Year | $36.37 | N/A |
| Revenue Next Year | $22.04 | $4.11 |
| P/E Ratio | $553.50 | ★ $15.20 |
| Revenue Growth | ★ 53.47 | 5.92 |
| 52 Week Low | $170.99 | $52.44 |
| 52 Week High | $385.22 | $66.81 |
| Indicator | ONC | SLF |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 46.44 |
| Support Level | $325.00 | $57.52 |
| Resistance Level | $340.98 | $59.43 |
| Average True Range (ATR) | 13.32 | 0.80 |
| MACD | -3.46 | -0.04 |
| Stochastic Oscillator | 16.88 | 50.00 |
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Sun Life Financial is one of the Big Three Canadian life insurers. The Canadian business contributed around 38% of adjusted earnings. In that segment, the firm provides health, life insurance, and annuity products to individual and group customers. Its US business is mostly group health and contributed about 20% of the firm's adjusted earnings in 2024. Sun Life also offers life insurance and wealth products in several Asian markets with a strong presence in Hong Kong and the Philippines. The Asia segment contributed around 18% of adjusted 2024 earnings. Its asset management business had around CAD 1.1 trillion total assets under management or administration at the end of 2024 and represents around 34% of the firm's earnings.